Andexanet alfa to reverse the effect of factor Xa inhibitors in intracranial hemorrhage
S Frol, JP Oblak, M Šabovič, P Kermer - CNS drugs, 2023 - Springer
Andexanet alfa (AA) is a recombinant factor Xa competing for binding with factor Xa
inhibitors, thereby reversing their anticoagulation effects. Since 2019, it has been approved …
inhibitors, thereby reversing their anticoagulation effects. Since 2019, it has been approved …
[HTML][HTML] Treatment of Factor-Xa Inhibitor-associated Bleeding with Andexanet Alfa or 4 Factor PCC: A Multicenter Feasibility Retrospective Study
AJ Singer, M Concha, J Williams… - Western Journal of …, 2023 - ncbi.nlm.nih.gov
Background There are no randomized trials comparing andexanet alfa and 4 factor
prothrombin complex concentrate (4F-PCC) for the treatment of factor Xa inhibitor (FXa-I) …
prothrombin complex concentrate (4F-PCC) for the treatment of factor Xa inhibitor (FXa-I) …
[HTML][HTML] Design and rationale for REVERXaL: A real-world study of patients with factor Xa inhibitor–associated major bleeds
R Alikhan, M Nour, M Yasaka, R Ofori-Asenso… - Thrombosis …, 2024 - Elsevier
Background The prevalence of anticoagulation treatment is increasing as an aging global
population faces a high burden of cardiovascular comorbidities. Direct oral anticoagulants …
population faces a high burden of cardiovascular comorbidities. Direct oral anticoagulants …
Activated Prothrombin Complex Concentrates for the Treatment of Factor Xa Inhibitor-Associated Spontaneous Intracerebral Hemorrhage
AS Rowe, LA Hamilton, JA Barber… - Journal of …, 2023 - journals.sagepub.com
Background: Anticoagulant-associated intracerebral hemorrhage (ICH) is a significant cause
of morbidity and mortality. Despite approval of a specific reversal agent for factor Xa …
of morbidity and mortality. Despite approval of a specific reversal agent for factor Xa …